Hyperactive cancer protein unexpectedly tamed


Thirty percent of all cancer cases are triggered by a faulty KRAS gene, resulting in runaway cell division. The cancers caused by this particular mutation - such as pancreatic cancer - are difficult to treat. At the Netherlands Cancer Institute, a team of researchers headed by Rene Bernards have made an unexpected discovery that may enable cancers with this mutation to be treated with targeted drugs in the future.

The details of their research were published in the Nature Medicine issue of 28 May 2018


This site uses cookies

This website uses cookies to ensure you get the best experience on our website.